Regulus Therapeutics Inc. (RGLS)

Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)

8.16

+0.02 (0.25%)

Inactive · Last trade price on Jun 24, 2025

Regulus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-47.52	-46.36	-30.04	-28.32	-27.81	-15.73
Depreciation & Amortization	0.35	0.35	0.23	0.12	0.46	0.47
Loss (Gain) From Sale of Investments	-1.89	-1.56	-0.16	-0.19	-	-
Stock-Based Compensation	9	7.74	2.8	2.18	2.92	2.61
Other Operating Activities	0.01	0.04	0.14	0.13	-0.62	0.15
Change in Accounts Receivable	-	-	-	-	0.5	0.64
Change in Inventory	-0.46	-0.48	-	-	0.3	0.61
Change in Accounts Payable	-0.21	0.74	0.03	-0.11	-0.25	-0.79
Change in Unearned Revenue	-	-	-	-	-	-0.01
Change in Other Net Operating Assets	-2.83	-2.14	0.23	0.66	0.36	-0.5
Operating Cash Flow	-43.54	-41.67	-26.77	-25.53	-24.13	-12.54
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Capital Expenditures	-0.11	-0.34	-0.61	-0.36	-0.25	-
Sale of Property, Plant & Equipment	-	-	0	-	-	-
Sale (Purchase) of Intangibles	-	-	-	-	-	-0.01
Investment in Securities	64.17	-35.64	15.1	-14.76	-	-
Investing Cash Flow	64.06	-35.98	14.49	-15.12	-0.25	-0.01

Financing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Long-Term Debt Issued	-	-	-	-	-	0.66
Long-Term Debt Repaid	-	-1.38	-3.3	-	-0.08	-10.28
Net Debt Issued (Repaid)	-0.55	-1.38	-3.3	-	-0.08	-9.62
Issuance of Common Stock	0.04	93.93	15.12	4.49	53.82	19.13
Other Financing Activities	-0.13	-0.13	-	-	-	-
Financing Cash Flow	-0.64	92.42	11.82	4.49	53.74	9.51

Net Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Cash Flow	19.87	14.76	-0.46	-36.16	29.36	-3.03

Free Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Free Cash Flow	-43.66	-42.01	-27.38	-25.89	-24.38	-12.54
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	-	-	-	-	-	-125.28%
Free Cash Flow Per Share	-0.66	-0.75	-1.44	-1.70	-2.85	-3.58
Levered Free Cash Flow	-25.61	-25.53	-16.93	-14.35	-15.81	-6.13
Unlevered Free Cash Flow	-25.55	-25.43	-16.56	-13.92	-15.28	-5

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash Interest Paid	0.03	0.07	0.45	0.49	0.73	1.36
Cash Income Tax Paid	0	0	0	0	0	0

SEC Filings: 10-K · 10-Q